ELEGEN

ELEGEN

Biotechnology

San Carlos, California 4,862 followers

Unlock the promise of synthetic biology by accelerating the Design-Build-Test-Learn cycle

About us

We are now at the dawn of the synthetic biology revolution, which will spawn new applications, markets, and business models, improving human lives in countless ways. This revolution will be driven by new technologies that enable DNA writing at speed and scale. To catalyze this revolution, Elegen is creating a suite of ground-breaking technologies to achieve DNA writing with unparalleled speed, cost, and quality. Elegen is unlocking the power to reprogram biology and create biologic solutions in order to solve some of humanity’s greatest challenges. Founded and led by Dr. Matthew Hill and located in San Carlos, CA, Elegen is a stealth-mode company that is well capitalized by top life science investors, including Andreessen Horowitz, 8VC, and KdT. The company is advised and staffed by leading biotechnology scientists and entrepreneurs, including Dr. Marc Unger, inventor of the Nanoflex™ valve and former CSO of Fluidigm. Dr. Hill has a PhD from Stanford and a proven track record of advancing innovative technologies from invention to commercial success.

Website
http://www.elegenbio.com
Industry
Biotechnology
Company size
11-50 employees
Headquarters
San Carlos, California
Type
Privately Held
Founded
2017
Specialties
microfluidics, hardware, synthetic biology, engineering, organic chemsitry, DNA Synthesis, molecular biology, and biology

Locations

Employees at ELEGEN

Updates

Similar pages

Browse jobs

Funding

ELEGEN 2 total rounds

Last Round

Series B

US$ 35.0M

See more info on crunchbase